Smart pump trial aims to tame tough diabetes cases
NCT ID NCT07509060
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a hybrid closed-loop insulin pump system (mylife CamAPS FX) can improve blood sugar control and quality of life in 30 adults with type 1 diabetes who have chronically high blood sugar and psychological challenges. Participants either start the pump immediately or after a 3-month delay. The main goals are to see if the pump increases time in a healthy blood sugar range and lowers HbA1c levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of Silesia in Katowice, Poland
Katowice, Poland
-
Poznan University of Medical Science, Poland
Poznan, Poland
-
University Hospital in Krakow
Krakow, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smart pen take the guesswork out of insulin dosing?
- AI takes the wheel: could a smart algorithm optimize insulin pumps from home?
- Can a common diabetes pill make insulin therapy safer and more effective for type 1 diabetes?
- Real-World test of automated insulin system aims to improve blood sugar control for type 1 diabetes
- Can a wearable sensor help young people with type 1 diabetes tame blood sugar swings?
- Can a smartphone app help teens tame type 1 diabetes?